Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Human endogenous retroviruses and multiple sclerosis: innocent bystanders or disease determinants?
The synthetic cannabinoid R(+)WIN55,212-2 augments interferon-β expression via peroxisome proliferator-activated receptor-α
MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study.
Microglia activation is associated with IFN-α induced depressive-like behavior.
Glatiramer acetate reduces the risk for experimental cerebral malaria: a pilot study.
Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects.
First proof for rituximab in IgG4-related disease
Architecture of human mTOR complex 1.
Reviewing the Unmet Needs of Patients with Multiple Sclerosis.
Reactive astrocytes form scar-like perivascular barriers to leukocytes during adaptive immune inflammation of the CNS.
FDA Accepts Filing of BETACONNECT™* for Relapsing-Remitting Multiple Sclerosis Patients Taking BETASERON® (interferon beta-1b)
Quantitative assays for anti-aquaporin-4 antibody with subclass analysis in neuromyelitis optica.
Application of fullerenes in nanomedicine: an update.
A 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum Disorder.
Gender identity disorders and multiple sclerosis risk: A national record-linkage study.
EFNS 2012
A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions.
A genome-wide association study of brain lesion distribution in multiple sclerosis.
Discontinuation of Disease-Modifying Treatment for Multiple Sclerosis
Immunology 2013
Guillain-Barré syndrome-like-onset neurosarcoidosis positive for immunoglobulin G anti-N-acetylgalactosaminyl-GD1a antibody.
Epidemiology of Neuromyelitis Optica in the United States: A Multicenter AnalysisEpidemiology of NMO.
Human herpesvirus 6 and effectiveness of interferon β1b in multiple sclerosis patients.
The Stigma Scale for Chronic Illnesses 8-Item Version (SSCI-8): Development, Validation and Use Across Neurological Conditions.

Pages